Cambridge Cognition Holdings PLC Speech recognition for clinical trials
June 07 2017 - 1:01AM
RNS Non-Regulatory
TIDMCOG
Cambridge Cognition Holdings PLC
07 June 2017
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')
Speech recognition for clinical trials
Cambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG,
'Company'), the neuroscience digital health company, is pleased to
announce its application of automatic speech recognition ("ASR")
technology to develop new products to enable scalable,
language-based clinical assessment to reduce clinical trial
variability and costs and increase overall clinical trial
efficiency.
The Company is now employing commercially available Artificial
Intelligence ("AI") and ASR technologies to make language-based
verbal cognitive assessments that are scalable, automated and
consistent, which in turn will reduce human error between trial
centres and between trial subjects. The first products are expected
to be available commercially in mid 2018.
Language is a unique human capability that exhibits measurable
changes in many psychiatric and neurological conditions including
Alzheimer's disease, depression and schizophrenia. To date it has
been difficult for clinical researchers to perform language-based
assessments or measure verbal cognitive changes without highly
trained experts. Now this new combination of speech recognition
technology with Cambridge Cognition's validated computerised tests
will make this possible.
This new platform, powered by AI, will allow innovative types of
language-based cognitive assessment raising the possibility of
delivering clinician-administered cognitive testing remotely and
directly into people's homes for health assessments and trial
subject profiling and triaging. The company also sees future
opportunities to provide a means of monitoring well-established
clinical interactions objectively for quality control, which will
reduce reliance on human raters. This could have a significant
impact on trial cost and speed of recruitment.
The Company's ASR-based technology will be unveiled formally at
the Alzheimer's Association Technology and Dementia preconference
in London on July 15 2017, where data from a proof of concept study
will be presented.
Jenny Barnett, PhD, Chief Scientific Officer, Cambridge
Cognition said: "We see significant opportunities to improve upon
rater-administered tests such as the MMSE and ADAS-cog. Rater costs
are a high proportion of clinical trial budgets. Reducing these
costs and inherent variability will help effective drugs get to
market faster and deliver better value for pharmaceutical and
biotechnology companies, clinicians and patients."
Steven Powell, PhD, Chief Executive Officer, Cambridge Cognition
said: "Alongside our existing, non-verbal cloud based and wearable
cognitive assessment products, this new speech-based platform will
provide solutions for delivering economic, clinically beneficial
clinical trials. This is another significant step in applying
innovative new technology to optimise drug development productivity
and patient engagement for our customers and partners and it will
be the third key technology advancement developed and launched by
our innovation team since its formation in 2015."
Notes to editors
Cambridge Cognition is a neuroscience digital health company
developing products to better understand, detect and treat brain
health conditions. The company's cognitive technologies accelerate
research and development of new treatments, enhance understanding
of the brain and measure cognitive health in patients
worldwide.
www.cambridgecognition.com
Enquiries
Cambridge Cognition Holdings PLC
Steven Powell, Chief Executive Tel: 01223 810
Officer 700
Noah Konig, Director of Marketing press@camcog.com
finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220
Geoff Nash / Simon Hicks 0500
Alice Lane (Corporate Finance)
(Corporate Broking)
Dowgate Capital Stockbrokers Limited Tel: 020 3903
(Joint Broker) 7715
David Poutney / James Serjeant
IFC Advisory Ltd (Financial PR Tel: 020 3053
and IR) 8671
Tim Metcalfe / Graham Herring /
Miles Nolan
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFMGGVFVVGNZM
(END) Dow Jones Newswires
June 07, 2017 02:01 ET (06:01 GMT)
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From Apr 2024 to May 2024
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From May 2023 to May 2024